148 related articles for article (PubMed ID: 38831284)
21. Immunogenic Cell Death Inducing Fluorinated Mitochondria-Disrupting Helical Polypeptide Synergizes with PD-L1 Immune Checkpoint Blockade.
Jeong SD; Jung BK; Ahn HM; Lee D; Ha J; Noh I; Yun CO; Kim YC
Adv Sci (Weinh); 2021 Apr; 8(7):2001308. PubMed ID: 33854870
[TBL] [Abstract][Full Text] [Related]
22. RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer.
Tentler JJ; Lang J; Capasso A; Kim DJ; Benaim E; Lee YB; Eisen A; Bagby SM; Hartman SJ; Yacob BW; Gittleman B; Pitts TM; Pelanda R; Eckhardt SG; Diamond JR
BMC Cancer; 2020 Nov; 20(1):1063. PubMed ID: 33148223
[TBL] [Abstract][Full Text] [Related]
23. Enhanced CTLA-4 blockade anti-tumor immunity with APG-157 combination in a murine head and neck cancer.
Shin DS; Basak S; Veena MS; Comin-Anduix B; Bhattacharya A; Dong TS; Ko A; Han P; Jacobs J; Moatamed NA; Avila L; Pellegrini M; Wang M; Srivatsan ES
Cancer Med; 2024 May; 13(9):e7212. PubMed ID: 38686626
[TBL] [Abstract][Full Text] [Related]
24. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR.
Zhou X; Du J; Wang H; Chen C; Jiao L; Cheng X; Zhou X; Chen S; Gou S; Zhao W; Zhai W; Chen J; Gao Y
Cell Commun Signal; 2020 Sep; 18(1):142. PubMed ID: 32894141
[TBL] [Abstract][Full Text] [Related]
25. Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer.
Clubb JHA; Kudling TV; Heiniö C; Basnet S; Pakola S; Cervera Carrascón V; Santos JM; Quixabeira DCA; Havunen R; Sorsa S; Zheng V; Salo T; Bäck L; Aro K; Tulokas S; Loimu V; Hemminki A
Front Immunol; 2022; 13():794251. PubMed ID: 35355980
[TBL] [Abstract][Full Text] [Related]
26. Tumor cell-intrinsic SETD2 inactivation sensitizes cancer cells to immune checkpoint blockade through the NR2F1-STAT1 pathway.
Zheng X; Luo Y; Xiong Y; Liu X; Zeng C; Lu X; Wang X; Cheng Y; Wang S; Lan H; Wang K; Weng Z; Bi W; Gan X; Jia X; Wang L; Wang Y
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056895
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer.
Yan C; Yang J; Saleh N; Chen SC; Ayers GD; Abramson VG; Mayer IA; Richmond A
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069042
[TBL] [Abstract][Full Text] [Related]
28. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
29. PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
Han MG; Jang BS; Kang MH; Na D; Kim IA
Eur J Cancer; 2021 Nov; 157():450-463. PubMed ID: 34601286
[TBL] [Abstract][Full Text] [Related]
30. UM171A-induced ROS promote antigen cross-presentation of immunogenic peptides by bone marrow-derived mesenchymal stromal cells.
Salame N; Bikorimana JP; El-Hachem N; Saad W; Kurdi M; Zhao J; Eliopoulos N; Shammaa R; Rafei M
Stem Cell Res Ther; 2022 Jan; 13(1):16. PubMed ID: 35012668
[TBL] [Abstract][Full Text] [Related]
31. The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors.
Bissonnette RP; Cesario RM; Goodenow B; Shojaei F; Gillings M
BMC Cancer; 2021 Aug; 21(1):969. PubMed ID: 34461854
[TBL] [Abstract][Full Text] [Related]
32. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment.
Yi M; Jiao D; Qin S; Chu Q; Wu K; Li A
Mol Cancer; 2019 Mar; 18(1):60. PubMed ID: 30925919
[TBL] [Abstract][Full Text] [Related]
33. Boiling histotripsy and in-situ CD40 stimulation improve the checkpoint blockade therapy of poorly immunogenic tumors.
Singh MP; Sethuraman SN; Miller C; Malayer J; Ranjan A
Theranostics; 2021; 11(2):540-554. PubMed ID: 33391491
[No Abstract] [Full Text] [Related]
34. The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1.
Yi M; Zhang J; Li A; Niu M; Yan Y; Jiao Y; Luo S; Zhou P; Wu K
J Hematol Oncol; 2021 Feb; 14(1):27. PubMed ID: 33593403
[TBL] [Abstract][Full Text] [Related]
35. Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy.
Schoonderwoerd MJA; Koops MFM; Angela RA; Koolmoes B; Toitou M; Paauwe M; Barnhoorn MC; Liu Y; Sier CFM; Hardwick JCH; Nixon AB; Theuer CP; Fransen MF; Hawinkels LJAC
Clin Cancer Res; 2020 Jul; 26(14):3831-3842. PubMed ID: 32332012
[TBL] [Abstract][Full Text] [Related]
36. Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice.
Pieper AA; Rakhmilevich AL; Spiegelman DV; Patel RB; Birstler J; Jin WJ; Carlson PM; Charych DH; Hank JA; Erbe AK; Overwijk WW; Morris ZS; Sondel PM
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172518
[TBL] [Abstract][Full Text] [Related]
37. A1-reprogrammed mesenchymal stromal cells prime potent antitumoral responses.
Gonçalves MP; Farah R; Bikorimana JP; Abusarah J; El-Hachem N; Saad W; Talbot S; Stanga D; Beaudoin S; Plouffe S; Rafei M
iScience; 2024 Mar; 27(3):109248. PubMed ID: 38433914
[TBL] [Abstract][Full Text] [Related]
38. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
[TBL] [Abstract][Full Text] [Related]
39. Cancer Cell Membrane Camouflaged Mesoporous Silica Nanoparticles Combined with Immune Checkpoint Blockade for Regulating Tumor Microenvironment and Enhancing Antitumor Therapy.
Zhao P; Qiu L; Zhou S; Li L; Qian Z; Zhang H
Int J Nanomedicine; 2021; 16():2107-2121. PubMed ID: 33737808
[TBL] [Abstract][Full Text] [Related]
40. Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment.
Song Y; Fu Y; Xie Q; Zhu B; Wang J; Zhang B
Front Immunol; 2020; 11():1956. PubMed ID: 32983126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]